Bullfrog Ai Holdings, INC 8-K filings

BullFrog AI Holdings, Inc. reported the results of its 2026 Annual Meeting and a significant base salary increase for its CEO.

BullFrog AI Holdings, Inc. announced it has regained compliance with Nasdaq's minimum stockholders equity requirement, extending its capital runway.

BullFrog AI Holdings, Inc. has scheduled its 2026 Annual Meeting of Stockholders for June 11, 2026, and updated shareholder proposal deadlines.

BullFrog AI Holdings, Inc. announced a commercial agreement with a top 5 global pharmaceutical company and secured financing to extend its operational runway into late 2027.

BullFrog AI Holdings, Inc. announced it believes it has regained compliance with Nasdaq's minimum stockholders equity requirement after raising at least $3.45 million.

BullFrog AI Holdings, Inc. announced a commercial agreement with a top-tier global pharmaceutical company to apply its AI platform for major depressive disorder drug target identification.

BullFrog AI Holdings, Inc. received a notice from Nasdaq indicating non-compliance with listing rules, potentially leading to delisting.

BullFrog AI Holdings, Inc. released its annual letter to shareholders, detailing significant 2025 progress and outlining key commercial priorities and potential catalysts for 2026.

BullFrog AI Holdings' stockholders approved a significant equity plan increase, a potential reverse stock split, and a share issuance to Lincoln Park Capital Fund.

BullFrog AI Holdings, Inc. received an extension from Nasdaq until February 17, 2026, to regain compliance with the stockholder equity requirement, avoiding immediate delisting.

Bullfrog AI Holdings, Inc. announced the results of its 2025 Annual Meeting of Stockholders, including the election of four directors and the ratification of its independent auditor, alongside an amendment to its bylaws reducing the quorum requirement.

BullFrog AI Holdings, Inc. entered into a purchase agreement with Lincoln Park Capital Fund, LLC for up to $10.0 million in common stock, providing flexible capital over 36 months.

BullFrog AI Holdings, Inc. received a Nasdaq deficiency notice for failing to meet minimum stockholder equity requirements while also approving new equity awards for executives and directors.

BullFrog AI Holdings, Inc. announced a strategic collaboration with Sygnature Discovery to introduce its AI-driven data insights platform to global biopharma clients, projecting $15-$30 million in revenue through 2028.

Bullfrog AI Holdings, Inc. has entered into an agreement with BTIG, LLC to sell up to $20 million of its common stock through an at-the-market offering.

BullFrog AI and Eleison Pharmaceuticals have entered into a collaboration agreement where BullFrog AI will leverage its AI platform to optimize Eleison's Phase 3 oncology clinical trials.

BullFrog AI's year-end letter to shareholders highlights advancements in their AI platform, key collaborations, and a strengthened financial position.

Bullfrog AI Holdings, Inc. has appointed Josh Blacher as its new Chief Financial Officer, effective immediately, following the passing of former CFO Dane Saglio.

Bullfrog AI Holdings, Inc. reports the passing of their Chief Financial Officer, Dane Saglio, on December 7, 2024.

BullFrog AI Holdings, Inc. has successfully raised approximately $3.13 million through a registered direct offering and concurrent private placement of common stock and warrants.

BullFrog AI has appointed Dr. John Baldoni, a former GSK executive, to its Scientific Advisory Board to enhance its drug development capabilities.

BullFrog AI has announced the publication of new research supporting the potential of their drug candidate, BF-114, in treating various liver diseases.

Bullfrog AI Holdings successfully held its 2024 Annual Meeting, electing four directors and ratifying its independent auditor.

BullFrog AI and the Lieber Institute for Brain Development have identified specific molecular pathways and potential drug targets related to bipolar disorder using AI-driven analysis.

BullFrog AI and the Lieber Institute for Brain Development have identified potential drug targets for neuropsychiatric conditions using AI and machine learning.

BullFrog AI's Chief Scientific Officer will present on the use of quantum computing in precision medicine at the Bio-IT World Conference & Expo.

BullFrog AI and the Lieber Institute for Brain Development have announced the availability of a fireside chat recording detailing their collaborative research using AI to analyze brain samples and identify biological subtypes of psychiatric disorders.

BullFrog AI has appointed Dr. Thomas W. Chittenden, a renowned expert in biomedical AI, as its new Chief Scientific Officer.

BullFrog AI and the Lieber Institute for Brain Development have successfully stratified brain expression data, potentially offering unprecedented insights into psychiatric conditions.

Bullfrog AI successfully priced and closed a public offering, raising approximately $5.7 million to support its AI-driven drug development initiatives.